GRIFOLS SA-ADR (GRFS)

US3984384087 - ADR

6.68  +0.03 (+0.45%)

After market: 6.6 -0.08 (-1.2%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GRIFOLS SA-ADR

NASDAQ:GRFS (3/28/2024, 8:14:07 PM)

After market: 6.6 -0.08 (-1.2%)

6.68

+0.03 (+0.45%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.54B
Shares
PE66.8
Fwd PE6.56
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GRFS Daily chart

Company Profile

Grifols SA engages in the production of plasma derivatives. The company is headquartered in Barcelona, Barcelona and currently employs 23,245 full-time employees. The company went IPO on 2006-05-17. The company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Company Info

GRIFOLS SA-ADR

C/ Jesus y Maria, 6

Barcelona BARCELONA 08174

P: 34935710000

CEO: Raimon Grifols Roura

Employees: 23245

Website: https://www.grifols.com/

GRFS News

News Image9 hours ago - TheNewswire.comGrifols, S.A. (NASDAQ: GRFS) Shareholder Alert: Kaplan Fox Investigates Claims on Behalf of Grifols, S.A. Investors

NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities.  Click Here to Join the Investigation.

News Image9 hours ago - NewMediaWireGrifols, S.A. (NASDAQ: GRFS) Shareholder Alert: Kaplan Fox Investigates Claims on Behalf of Grifols, S.A. Investors

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Imagea day ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are...

News Imagea day ago - TheNewswire.comGrifols, S.A. (NASDAQ: GRFS) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. for Potential Securities Violations

NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities.  Click Here to Join the Investigation.

News Imagea day ago - NewMediaWireGrifols, S.A. (NASDAQ: GRFS) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. for Potential Securities Violations

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image6 days ago - TheNewswire.comKaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. (Nasdaq: GRFS)

NEW YORK, NY - (NewMediaWire) - March 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.

GRFS Twits

Here you can normally see the latest stock twits on GRFS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example